StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a research report released on Saturday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Lipocine Trading Down 2.3 %
Lipocine stock opened at $4.62 on Friday. The stock has a fifty day moving average price of $4.60 and a 200 day moving average price of $3.59. Lipocine has a 52 week low of $2.31 and a 52 week high of $7.15. The firm has a market capitalization of $24.72 million, a P/E ratio of -1.51 and a beta of 1.05.
Lipocine (NASDAQ:LPCN – Get Free Report) last posted its quarterly earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.11. The business had revenue of $0.22 million during the quarter. As a group, equities analysts predict that Lipocine will post -1.49 EPS for the current year.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Read More
- Five stocks we like better than Lipocine
- How to Invest in Blue Chip Stocks
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Insider Trades May Not Tell You What You Think
- Hilton Demonstrates Asset Light is Right for Investors
- What is the S&P 500 and How It is Distinct from Other Indexes
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
